Enrico Proietti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.

Journal: Frontiers in oncology

Published: January 16, 2023

Nicotinamide inhibits melanoma in vitro and in vivo.

Nicotinamide inhibits melanoma in vitro and in vivo.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 30, 2020

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade.

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade.

Journal: Cells

Published: March 18, 2020

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy.

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy.

Journal: Cancer immunology, immunotherapy : CII

Published: October 30, 2019

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.

Journal: Frontiers in oncology

Published: October 16, 2019

Type I interferons induce peripheral T regulatory cell differentiation under tolerogenic conditions.

Type I interferons induce peripheral T regulatory cell differentiation under tolerogenic conditions.

Journal: International immunology

Published: April 03, 2019

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.

Journal: Oncoimmunology

Published: January 18, 2018

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Journal: Cancer immunology research

Published: November 24, 2017

Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.

Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: September 29, 2017

The added value of type I interferons to cytotoxic treatments of cancer.

The added value of type I interferons to cytotoxic treatments of cancer.

Journal: Cytokine & growth factor reviews

Published: May 31, 2017

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

Journal: Cytokine & growth factor reviews

Published: May 15, 2017

Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.

Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.

Journal: International journal of cancer

Published: March 29, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026